A Johnson & Johnson building is shown in Irvine, California, January 2017. (Mike Blake/Reuters)
The Food and Drug Administration will attach a label to the Johnson & Johnson coronavirus vaccine warning of a slightly increased risk of a rare nerve disorder known as Guillain-Barre syndrome.
Just 100 out of about 9,800,000 Americans who received the Johnson & Johnson vaccine developed the neurological condition. However, the FDA chose to add a warning label because the risk of developing Guillain-Barre syndrome is believed to be roughly three to five times higher in those who have taken the Johnson & Johnson vaccine.
“It’s not surprising to find these types of adverse events associated with vaccination,” Dr. Luciana Borio, a former acting chief scientist at the FDA, told the New York Times. The vaccine’s benefits “continue to vastly outweigh the risks.”
Continue reading on National Review